Panacea Biotec Ltd

Panacea Biotec Ltd share price gained 3.50% to Rs 414.05 after the company's net profit witnessed a sharp fall of 320% to Rs 2.2 crore, while revenue from operations increased 19.68% to Rs 199.57 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.19 lakh crore, rising 4.61%. It has improved by 0.99% over last one week and advanced by 11.20% in last one month while the market capitalization of Panacea Biotec Ltd has eased by 0.85% and 6.99% in the same period respectively. Profit before tax (PBT) of Panacea Biotec Ltd stood at Rs 3.57 crore in Q2 FY26, tumbling by 45.58% year-on-year, and plunging by 385.60% quarter-on-quarter. EBITDA came in at Rs 1 crore, tanking 120.88% YoY and rallying 7050.00% sequentially. Total expenses went up by 17.28% to Rs 201.8 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 74.17 crore, softening by 8.18% YoY, while employee benefits expense was at Rs 44.16 crore, slipping by 5.68% YoY. For the TTM ended FY26, revenue from operations remained flat to Rs 559.09 crore, while net profit soared by 481.33% to Rs 8.72 crore, compared to previous TTM. EBITDA plunged by 4876% to Rs 46.57 crore, and PBT collapsed by 637.16% to Rs 7.95 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 27.37 crore in FY26, as against Rs 3.47 crore in FY25. Panacea Biotec Ltd dropped 7.13% in last one year, significantly underperforming the benchmark BSE Sensex which has eased by 2.83% during the same period.

Panacea Biotec Limited will hold a board meeting on August 13, 2026, in New Delhi, to approve the standalone and consolidated unaudited financial results (provisional) for the quarter ended June 30, 2026, according to a regulatory filing. The company’s trading window for designated persons and their immediate relatives will remain closed from July 1, 2026, to August 15, 2026.

Panacea Biotec Ltd. is up 1.30% to Rs 424.85, extending recent gains and rising 0.24% over the last one week. Panacea Biotec Ltd. has received a Letter of Award from UNICEF for the supply of bivalent Oral Polio Vaccine (bOPV) in Calendar Year 2028, valued at approximately US$8.205 million (Rs 78.24 Crore), as part of a Long-Term Agreement initiated in April 2026. This award, for both 10 and 20 dose presentations, follows a previous award announced on October 3, 2025, and represents an international contract for the supply of bOPV to UNICEF. Trading volume reached 1.46 lakh shares today, a marginal increase of 10.03% compared to the average volume over the past week. Panacea Biotec Ltd. edged up by 0.89% year-over-year, outperforming the NIFTY50 index's 0.44% loss.

Agri-Tech (India) Ltd, Orbit Exports Ltd, Shardul Securities Ltd and Creative Eye Ltd are among the other losers in the BSE's 'B' group today, 10 June 2026.Panacea Biotec Ltd crashed 9.99% to Rs 547.65 at 14:31 IST.The stock was the biggest loser in the BSE's 'B' group.On the BSE, 1.52 lakh shares were traded on the counter so far as against the average daily volumes of 75434 shares in the past one month.Agri-Tech (India) Ltd tumbled 9.97% to Rs 122.8. The stock was the second biggest loser in 'B' group.On the BSE, 7168 shares were traded on the counter so far as against the average daily volumes of 2625 shares in the past one month.Orbit Exports Ltd lost 9.47% to Rs 198. The stock was the third biggest loser in 'B' group.On the BSE, 936 shares were traded on the counter so far as against the average daily volumes of 1597 shares in the past one month.Shardul Securities Ltd shed 9.02% to Rs 27.25. The stock was the fourth biggest loser in 'B' group.On the BSE, 1367 shares were traded on the counter so far as against the average daily volumes of 1775 shares in the past one month.Creative Eye Ltd plummeted 7.95% to Rs 6.25. The stock was the fifth biggest loser in 'B' group.On the BSE, 116 shares were traded on the counter so far as against the average daily volumes of 2505 shares in the past one month.Powered by Capital Market - Live

Panacea Biotec announced the launch of the DENSTAR project which will work to advance the licensure of the dengue vaccine DengiAll' in sub-Saharan Africa (sSA) and to facilitate its broader global use. The four-year initiative is funded under the Global Health European & Developing Countries Clinical Trials Partnership 3 Joint Undertaking (GH EDCTP3 JU), supported by the European Union and aligns with the EDCTP3 mission to combat Neglected Tropical Diseases (NTDs), including dengue fever, and seeks to reduce the disease burden across Africa. The DENSTAR project is coordinated by the 'Sclavo Vaccines Association', a non-profit organization based in Siena (Italy) devoted to support vaccine research and development in developing countries. The DENSTAR consortium unites 10 Partners from 9 countries across Europe, Africa, the United States, India and South Korea which comprises of universities, research organizations, a biotech company and a non profit organization, bringing together experts, researchers, regulators, healthcare practitioners. Panacea Biotec being the developer of DengiAll', a tetravalent dengue vaccine targeting all four virus serotypes and currently in late-stage development in India, is a key partner of the DENSTAR consortium. This diverse and complementary consortium embodies a great public-private partnership, fully aligned with the DENSTAR project's goal to promote broader use of DengiAll' in Africa and globally, contributing to equitable access to safe and effective dengue prevention tools.

Net profit of Panacea Biotec reported to Rs 0.52 crore in the quarter ended March 2026 as against net loss of Rs 1.89 crore during the previous quarter ended March 2025. Sales rose 25.82% to Rs 166.75 crore in the quarter ended March 2026 as against Rs 132.53 crore during the previous quarter ended March 2025. For the full year,net loss reported to Rs 5.37 crore in the year ended March 2026 as against net loss of Rs 8.37 crore during the previous year ended March 2025. Sales rose 14.43% to Rs 639.77 crore in the year ended March 2026 as against Rs 559.09 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales166.75132.53 26 639.77559.09 14 OPM %1.54-20.28 --0.73-4.63 - PBDT3.92-19.33 LP 6.19-9.13 LP PBT-3.96-27.75 86 -26.87-43.94 39 NP0.52-1.89 LP -5.37-8.37 36 Powered by Capital Market - Live

Panacea Biotec will hold a meeting of the Board of Directors of the Company on 29 May 2026.

Securities in F&O Ban: Sammaan Capital and Steel Authority of India shares are banned from F&O trading on 13 April 2026. Result Today: ICICI Prudential Asset Management Company, Just Dial, Swaraj Engines, Innovision, Parin Enterprises, Indbank Housing and Continental Controls will announce their quarterly earnings today. IPO Opening: Om Power reported 0.71x subscription on Day 2 Om Power's initial public offering (IPO) was subscribed 0.71 times overall on Day 2 (as of 5:00 PM), with Qualified Institutional Buyers (QIBs) subscribing 1.18 times, the retail portion at 0.58 times, and Non-Institutional Investors (NIIs) at 0.38 times. Stocks to Watch: Panacea Biotec announced that it has received a letter of award (LoA) worth Rs 20.79 crore from Central Medical Services Society, under the Ministry of Health and Family Welfare, Government of India. Advance Agrolife announced that it has received a letter of intent (LoI) worth Rs 30.37 crore from National Fertilizers for the supply of various agrochemicals. Zaggle Prepaid Ocean Services announced that it has entered into an agreement with Generali Central Insurance Company (formerly known as Future Generali India Insurance Company Limited) to provide its Zaggle Zoyer platform. Emerald Leisures said that it has received a letter of intent (LoI) for the development of a residential redevelopment project at Swastik Park, Chembur in Mumbai, with an estimated revenue potential of around Rs 600 crore. Larsen & Toubro said its real estate arm, L&T Realty Properties, has acquired a 100% stake in International Green Scapes for Rs 1,123 crore in an all-cash deal, as it looks to expand its residential portfolio in Gurugram. Airfloa Rail Technology said that it has secured a domestic order worth Rs 1.25 crore from Rail Coach Factory Kapurthala for the supply of luggage rack modules for LHB non-AC and AC chair car coaches. Blue Dart Express reported a low-severity cyber security incident within its parent group. The company said the incident involved phishing and impersonation exposure. It clarified that no sensitive data was breached and no customer or business information was impacted. Swiggy's Co-founder Nandan Reddy has stepped down to pursue personal projects, while Chief Growth Officer Phani Kishan and Group CFO Rahul Bothra will join the board as Executive Directors. Laxmi Organic announced that it has appointed Harshvardhan Goenka as Interim CFO following the resignation of Mahadeo Karnik. LIC Housing Finance announced that it has appointed Sanjay Dayal as its Chief Operating Officer (COO).

As per the terms, the company will supply Diphtheria and Tetanus Vaccine (Absorbed) for Adults and Adolescents (Td Vaccine) in multiple tranches. The supplies are scheduled to commence from September/October 2026 and continue till November/December 2028. The company clarified that the order has been awarded by a domestic entity and is in the nature of vaccine supply. It further stated that neither its promoters nor promoter group entities have any interest in the awarding authority, and the transaction does not fall under related-party transactions. Panacea Biotec is a research-based biotechnology company engaged in the business of research, development, manufacture, and marketing vaccines in India and international markets. The company reported a consolidated net loss of Rs 7.36 crore in Q3 FY26 as against a net profit of Rs 9.65 crore in Q3 FY25. Revenue from operations declined 8.4% year on year to Rs 99.31 crore in Q3 FY26. Shares of Panacea Biotec rose 1.23% to end at Rs 326 on 10 April 2026.

Panacea Biotec announced that Mukul Gupta (DIN: 00254597), Independent Director of the Company has completed his second and final term of 5 (five) consecutive years as Independent Director on 31 March 2026 and accordingly he has ceased to be an Independent director of the Company.